http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-0859610-B1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_468ba69b8e2068e9319b9942dcc081b3 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_cea72e2de3c0219165474e54e9842d16 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D487-22 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-55 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-55 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D487-22 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D471-22 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-33 |
| filingDate | 1996-08-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2006-01-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_60028d6fd4cc4729545a555cda4e09a3 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_46c6b81fc625850b71a39365e009b18a |
| publicationDate | 2006-01-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | EP-0859610-B1 |
| titleOfInvention | Ibogamine congeners |
| abstract | The present invention is directed to compounds having formula (1), wherein n is from 0 to 8; R1 is CH2OH, CH(OH)R5, CH2OR5, CO2R5, C(O)NH2, C(I)NHR5, C(O)NR5R6, C(O)NHNH2, C(O)NHNHR5, C(O)NHNR5R6, C(O)NR5NH2, C(O)NR5NHR6, C(O)NR5NR6R7, C(O)NHNH(C(O)R5), C(O)NHNR5(C(O)R6) C(O)NR5NH(C(O)R6), C(O)NR5NR6(C(O)R7), CN, or C(O)R5; R2 is H, unsubstituted or substituted alkyl, YH, YR8, YC(O)R8, C(O)YR8, C(O)NH2, C(O)NHR8, C(O)NR8R9, NH2, NHR8, NR8R9, NHC(O)R8, or NR8C(O)R9; R3 and R4 are the same or different and are selected from the group consisting of H, halogens, unsubstituted or substituted alkyl, OH, OR10, NH2, NHR10, NR10R11, NHC(O)R10, or NR10C(O)R11; R5, R6, R7, R8, R9, R10, and R11 are the same or different and are selected from the group consisting of unsubstituted alkyl and substituted alkyl and substituted alkyl; R12 is selected from the group consisting of J, unsubstituted alkyl, and substituted alkyl; and Y is O or S; provided that when n is O, R2 is selected from the group consisting of H, substituted alkyl, and unsubstituted alkyl; and pharmaceutically acceptable salts |
| priorityDate | 1995-08-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 436.